Also trades as: 0QAH.L (LSE) · $vol 5M · 6MK.DE (XETRA) · $vol 0M · MRK.TO (TSX) · $vol 0M · MRK.PA (PAR) · $vol 0M
MRK NYSE
Merck & Co., Inc.
1W: -3.0%
1M: -4.3%
3M: +13.8%
YTD: +35.6%
1Y: +61.5%
3Y: +49.1%
5Y: +123.8%
$144.30
+0.49 (+0.34%)
Weekly Expected Move ±2.6%
$137
$141
$144
$148
$152
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
4 neutral
0 bearish
Articles (24h)
4
Hourly Sentiment (24h)
0.25
Neutral
11 bullish
10 neutral
4 bearish
Articles (7d)
25
Daily Sentiment (7 Days)
Articles (100)
AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot
Moderna, Illumina lead healthcare gains in September as medtech drags
3 Income Stocks Under $30 That Yield More Than the 10-Year Treasury Note
Merck & Co., Inc. $MRK Stake Trimmed by CX Institutional
3 of the Best ETFs to Buy and Hold if a Recession Is Coming
Medicare drug pricing model to affect only four firms after Trump’s MFN policy
Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study
ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell?
FDA launches recruitment drive to add members to advisory panels
Why Merck (MRK) Dipped More Than Broader Market Today
Top Analyst Reports for Apple, Microsoft & Broadcom
Prediction: Moderna Stock Will Soar 100% by 2030
2 Outstanding Dividend Stocks to Buy and Hold for a Decade
Pharmaceutical industry lobbying group names new CEO, Eric Cantor
Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?
Merck succeeds in mid-stage trial for skin disease drug
Moderna slips as Citi cuts to Sell on “unjustifiable” valuation
SCHD's Top Sector Bet Is Healthcare at 20.7%. I'm Not Sure What's More Surprising: What It Doesn't Hold, or What It Does.
CDC data now show two measles deaths for 2026; Pennsylvania records four
Merck Inks $2.1B Deal With Chinese Biotech to Expand Oncology Pipeline
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Merck, Daiichi Withdraw FDA Filing for Lung Cancer Therapy
FDA Expands Merck's Welireg Label for a New Kidney Cancer Indication
Is AstraZeneca's Oncology Portfolio Positioned for Continued Growth?
Merck signs up to $2.13B license deal with SciBrunch
Merck pulls BLA for antibody-drug conjugate I-DXd for small cell lung cancer
Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study
Merck Welireg, Eisai Lenvima combo approved for kidney cancer
FDA commissioner nominee Overton rebuffs questions about Trump medical claims
Can Recent Traction With Key Drugs and Pipeline Progress Boost BMY?
Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans?
Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?
Beyond Imbruvica: Can AbbVie Rebuild Its Oncology Portfolio?
Merck’s diabetic macular edema therapy succeeds in Phase 2b/3 trial
Envestnet Portfolio Solutions Inc. Has $13.56 Million Stock Holdings in Merck & Co., Inc. $MRK
Merck (MRK) Declines More Than Market: Some Information for Investors
CDC acknowledges one Pennsylvania measles death
Wall Street Analysts Think Merck (MRK) Is a Good Investment: Is It?
MRNA Hits 52-Week High: How Melanoma Study Results Keep Rally Going
Merck says FDA approved label update for PAH therapy Winrevair
BioNTech Stock Recently Got Downgraded. But Is Wall Street Underestimating Its Cancer Pipeline?
Merck Gets CHMP Backing for Keytruda-Padcev Combo in Bladder Cancer
AZN vs. MRK: Comparing Keytruda, Pipelines and Growth Strategies
OPK Stock Climbs 32.5% YTD: What's Driving the Rally in 2026?
4 stocks to watch on Monday: HPQ, PFE, MRK, and MRVL
Merck secures Japanese approval for subcutaneous Keytruda
Healthcare stocks with the strongest dividend growth grades
RFK Jr. replaces federal autism panel chair: report
Trump to 'demand' vaccine makers make smaller doses for kids to address autism
Trump set to announce MFN pricing for Medicaid in all states
Merck, Astra, Roche and Corcept among winners of EU drug recommendations this week
Trump administration is said to weigh allowing most pharma licensing deals with China
BioNTech Threw in the Towel on Its Colorectal Cancer Vaccine Trial. Should Investors Be Worried?
Merck (MRK) Outperforms Broader Market: What You Need to Know
Looming biosimilar void risks $189B in lost U.S. healthcare savings: report
Pennsylvania calls on CDC to recognize measles deaths, asks for emergency assistance
JEPI and JEPQ Yield Way More Than SCHD, but SCHD Could Produce More Passive Income Over the Long Term. Here's Why.
Coca-Cola plans to invest $10B in U.S. infrastructure to meet rising demand
HHS to launch autism research initiative utilizing AI: report
Measles claims fourth death in Pennsylvania amid rising vaccine hesitancy
Is Cancer the Turnaround Moderna Has Been Looking for Post-COVID?
FDA launches pilot program that aims to speed the time to first-in-human drug trials
Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study
Moderna's COVID Vaccine Was a Historic Success. Could Its Cancer Vaccine Be Even Bigger?
Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?
Can Pfizer Overcome Its COVID and Patent Cliff Headwinds?
Blue-Chip Stocks Are Looking Anything But Boring With Dividends and Big 2026 Gains
Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial
2 Outstanding Dividend Stocks to Buy and Hold for 10 Years
MRK Banks on Growing Pipeline & New Drugs to Offset Keytruda LOE
These 5 ETFs Are Built for Bear Markets. History Says Now Is a Fantastic Time to Buy.
Merck (MRK) Dips More Than Broader Market: What You Should Know
GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff
Can Papzimeos Drive Precigen's Growth Through the Rest of 2026?
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
Archford Capital Strategies LLC Has $3.52 Million Position in Merck & Co., Inc. $MRK
25 dividend stocks to watch as market sentiment turns negative
The Zacks Analyst Blog Highlights Oracle, Merck, Union Pacific, CVD Equipment and Koil Energy Solutions
Pyxis slides after new early-stage trial data for lead asset in head and neck cancer
Baird Financial Group Inc. Sells 98,410 Shares of Merck & Co., Inc. $MRK
FDA names acting heads of drug and vaccine units to permanent roles
Top Stock Reports for Oracle, Merck & Union Pacific
MRNA Stock Soars 143% in a Month: Time to Buy, Hold or Sell?
Inhibrx cancer therapy outperforms Merck’s Keytruda in mid-stage trial
Merck Trading Near 52-Week High: Is the Stock a Buy, Hold or Sell?
Healthcare August recap: Moderna jumps 156% as biotech shines; DaVita sinks
Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Wall Street Has Cooled on Moderna After Its Stock Jumped Over 5X. But Does the mRNA Leader Have More Room to Run?
SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China
Allen Mooney & Barnes Investment Advisors LLC Has $16.29 Million Holdings in Merck & Co., Inc. $MRK
BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?
Moderna slips as Rothschild issues rare Sell rating after cancer vaccine-led rally
Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?
Why Is Merck (MRK) Up 18.2% Since Last Earnings Report?
Pfizer's Pipeline Strategy Centers on Obesity and Oncology
Is BioNTech Stock a No-Brainer Buy on the Dip?
If the AI Boom Slows Down, History Says This Is the Smartest Way to Protect Your Long-Term Portfolio
AZN Stock Down 20% in 6 Months: How to Play After Pipeline Setbacks
Can LLY's Merida Deal Boost Its M&A Push to Diversify Beyond GLP-1s?
Can Bixlenvo Unlock New Growth for Gilead's HIV Business?